Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Hospitalised medical patients are at significant risk of venous thromboembolic disease through fatal pulmonary embolism; low-molecular-weight heparins have been proved efficient in preventing deep venous thrombosis in surgical and medical patients, but their effect on mortality in bedridden medical patients remains unknown.
In a multi-centre, randomised, double-blind, placebo-controlled study, 2,474 consecutive patients aged over 40 years admitted to internal medicine departments in the last 24 h and unable to move alone were randomised to receive 0.3 ml nadroparin (7,500 anti-Xa units) or placebo for up to 21 days. The primary end-point was overall mortality at day 21.
There were no significant differences between the patients’ characteristics. Overall mortality between the two groups was not statistically different [10.08% (124 of 1,230) versus 10.29% (128 of 1,244), respectively, in the nadroparin and in the placebo groups; relative risk reduction 0.02, CI (−0.27, +0.25), P=0.89]. An autopsy was performed in 123 of the 252 patients who died (49%). Pulmonary embolism was discovered at autopsy in 10 of 63 patients in the nadroparin group and in 17 of 60 in the placebo group [relative risk reduction 0.38, CI (−0.27, +0.70), P=0.13].
Nadroparin does not have a significant effect on mortality in bedridden medical patients, based on the study results. The study provides no data suggesting that low-molecular-weight heparins might reduce the incidence of thromboembolic in-patients hospitalised for an acute medical disease.
- Geerts W, Heit JA, Clagett GP et al (2001) Prevention of venous thromboembolism. Chest 119:132–175 CrossRef
- THRIFT Consensus Group (1992) Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 305:567–572
- Sandler DA, Martin JF (1989) Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 82:203–205
- Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ (1982) Factors associated with an antemortem diagnosis of major pulmonary embolism. Am J Med 73:822–826 CrossRef
- Antiplatelet Trialists’ Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308:81–106
- Halkin H, Goldberg J, Modan M, Modan B (1982) Reduction of mortality in general medical in-patients by low dose heparin prophylaxis. Ann Intern Med 96:561–565
- Mismetti P, Laporte-Simitsidis S, Tardy B et al (2000) Prevention of venous thromboembolism in internal medicine with unfractioned or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83:14–19
- Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M, Herbecq P, Pordes R, Poussel JF, Roux L (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The association of non-university affiliated intensive care specialist physicians of France. Am J Respir Crit Care Med 161:1109–1114
- Bergmann JF, Caulin C (1996) Heparin prophylaxis in bedridden patients. Lancet 348:205–206 CrossRef
- Samama MM, Thomas AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 341:793–800
- Leizorovicz A, Cohen AT, Turpie AG et al (2004) PREVENT medical thromboprophylaxis study group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879 CrossRef
- Gardlund B (1996) Randomised controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious disease. The heparin prophylaxis study group. Lancet 347:1357–1361 CrossRef
- Chauvenet M, Caulin C. Les exigences pour une AMM européenne d’un médicament de la thrombose. In: «Les médicaments de la thrombose. Nouveautés dans l’évaluation et l‘utilisation ». Ed Springer. pp 39–76
- Dahan R, Houlbert D, Caulin C et al (1986) Prevention of deep venous thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 16:159–164
- Samama MM, Gerotziafas GT (2000) Comparative pharmacokinetics of LMWHs. Semin Thromb Haemost 26(Suppl1):31–38 CrossRef
- Breddin HK (2000) Prophylaxis and treatment of deep-venous thrombosis. Semin Thromb Haemost 26(Suppl1):47–52 CrossRef
- Collignon F, Frydman A, Caplain H et al (1995) Comparison of the pharmacokinetic profiles of three low molecular mass heparins—dalteparin, enoxaparin and nadroparin—administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–640
- Mahé I, Drouet L, Chassany O, Grenard AS, Caulin C, Bergmann JF (2002) Low molecular weight heparin for the prevention of deep venous thrombosis: a suitable monitoring in elderly patients? Pathophysiol Haemost Thromb 32:134–136
- Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study
European Journal of Clinical Pharmacology
Volume 61, Issue 5-6 , pp 347-351
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors